GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » FCF Yield %

AVANIR Pharmaceuticals (FRA:AV2B) FCF Yield % : 0.00 (As of May. 17, 2024)


View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, AVANIR Pharmaceuticals's Trailing 12-Month Free Cash Flow is €-38.08 Mil, and Market Cap is €2,686.27 Mil. Therefore, AVANIR Pharmaceuticals's FCF Yield % for today is 0.00%.

The historical rank and industry rank for AVANIR Pharmaceuticals's FCF Yield % or its related term are showing as below:


FRA:AV2B's FCF Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: -0.51
* Ranked among companies with meaningful FCF Yield % only.

AVANIR Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2014 was -23.39%.


AVANIR Pharmaceuticals FCF Yield % Historical Data

The historical data trend for AVANIR Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals FCF Yield % Chart

AVANIR Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.36 -15.46 -12.54 -10.38 -2.21

AVANIR Pharmaceuticals Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.08 -9.14 -11.56 -7.20 -1.31

Competitive Comparison of AVANIR Pharmaceuticals's FCF Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVANIR Pharmaceuticals's FCF Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's FCF Yield % falls into.



AVANIR Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

AVANIR Pharmaceuticals's FCF Yield % for the fiscal year that ended in Sep. 2014 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-40.129 / 1817.233759
=-2.21%

AVANIR Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Sep. 2014 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-5.937 * 4 / 1817.233759
=-1.31%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AVANIR Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


AVANIR Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines